SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001720725-21-000073
Filing Date
2021-08-05
Accepted
2021-08-05 16:04:43
Documents
14
Period of Report
2021-08-05
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K oyst-20210805.htm   iXBRL 8-K 38026
2 EX-99 oystearningspressrelease-q.htm EX-99 86958
6 oyster_pointxlogoxtmxrgba.jpg GRAPHIC 50247
  Complete submission text file 0001720725-21-000073.txt   350301

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT oyst-20210805.xsd EX-101.SCH 1905
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT oyst-20210805_lab.xml EX-101.LAB 24831
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT oyst-20210805_pre.xml EX-101.PRE 13045
7 EXTRACTED XBRL INSTANCE DOCUMENT oyst-20210805_htm.xml XML 11206
Mailing Address 202 CARNEGIE CENTER SUITE 109 PRINCETON NJ 08540
Business Address 202 CARNEGIE CENTER SUITE 109 PRINCETON NJ 08540 (609) 382-9032
Oyster Point Pharma, Inc. (Filer) CIK: 0001720725 (see all company filings)

IRS No.: 811030955 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39112 | Film No.: 211148102
SIC: 2836 Biological Products, (No Diagnostic Substances)